Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | editorial

Breast cancer—advanced stage: “cure—still a long way to go?”

verfasst von: Herbert Stöger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Excerpt

Metastatic breast cancer (MBC) remains essentially incurable, and goals of therapy include the palliation of symptoms, delay of disease progression, and prolongation of overall survival time without negatively impacting quality of life. Though numerous randomized clinical trials have shown improvements in overall response rates, few have found clear survival benefits. In recent years, however, there has been a small but growing series of clinical trials demonstrating modest, but meaningful survival advantages in metastatic disease [1]. In addition, the development of targeted biologic agents active against MBC, such as trastuzumab, has demonstrated great potential for enhancing the effects of chemotherapy and producing meaningful survival improvements, and thereby presents a new dimension [2]. …
Vorheriger Artikel Cellular immunotherapy for cancer. Past, present, future
Nächster Artikel Clinical practice guidelines in oncology—achievements and challenges
Literatur
1.
Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.CrossRefPubMed
2.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.CrossRefPubMed
3.
Greenberg PA, Hortobagyi GN, Smith TL, et al. Long term follow-up of patients with complete remission following chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.PubMed
4.
Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100:44–52.CrossRefPubMed
5.
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.CrossRefPubMed
Metadaten
Titel
Breast cancer—advanced stage: “cure—still a long way to go?”
verfasst von
Herbert Stöger, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0022-3

Weitere Artikel der Ausgabe 2/2012

Lung cancer screening: current evidence and recommendations

  • short review

Advances in haematology and oncology 2011: hepatocellular carcinoma (HCC)

  • comment

Interventional therapy for symptomatic bronchial carcinoma

  • review

Natural killer cell based immunotherapy for eradication of minimal residual disease in patients with malignant disorders

  • short review

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

  • short review

Is distinct EGFR mutation status proof of second simultaneous primary non-small cell lung cancer?

  • case report